AR and neoplasm: In addition to assessing the variation in individual genes encoding molecular targets for specific therapeutics, we also use DSP to categorize tumor phenotypes based on gene expression programs that indicate the activity of androgen receptor (AR) activity, neuroendocrine (NE) differentiation, and FGFR/MEK signaling, as well as the composition of immune cells and immunomodulatory cytokines and chemokines.